MidFirst Bank’s Novartis NVS Stock Holding History

MidFirst Bank’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.7K	Hold	30	–	–	﹤0.01%	586
2026 Q1	$4.58K	Sell	30 -260	-90%	-$39.9K	﹤0.01%	587
2025 Q4	$0	Buy	+290	New	+$38K	﹤0.01%	786

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

CCM

Cullen Capital Management New York $10.2B AUM 27.15% 1-Year Est. Return

MidFirst Bank's NVS Position: Q2 2026 in Review

MidFirst Bank held its Novartis (NVS) position steady in Q2 2026 at 30 shares worth $4.7K. The position accounts for ﹤0.01% of the portfolio, ranked #586.

MidFirst Bank first reported a position in NVS in Q4 2025 and has held it in 3 quarters since. 1,377 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

MidFirst Bank held 30 shares of Novartis worth $4.7K as of Q2 2026.
MidFirst Bank left its Novartis share count unchanged in Q2 2026.
Novartis made up ﹤0.01% of MidFirst Bank's portfolio in Q2 2026, its #586 holding.
MidFirst Bank first reported a position in Novartis in Q4 2025 and has held it in 3 quarters since.
1,377 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on MidFirst Bank's 13F filing for Q2 2026, filed 7 Aug 2026.